CN111423484A - β sitosterol derivative and preparation method and application thereof - Google Patents
β sitosterol derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN111423484A CN111423484A CN202010136016.0A CN202010136016A CN111423484A CN 111423484 A CN111423484 A CN 111423484A CN 202010136016 A CN202010136016 A CN 202010136016A CN 111423484 A CN111423484 A CN 111423484A
- Authority
- CN
- China
- Prior art keywords
- sitosterol
- derivative
- preparation
- sleep
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108090001008 Avidin Proteins 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 46
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 31
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 31
- 229950005143 sitosterol Drugs 0.000 claims description 31
- 229940076810 beta sitosterol Drugs 0.000 claims description 26
- 229960002685 biotin Drugs 0.000 claims description 25
- 239000011616 biotin Substances 0.000 claims description 24
- 235000020958 biotin Nutrition 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 230000007958 sleep Effects 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- -1 microneedle Substances 0.000 claims description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012024 dehydrating agents Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000003405 delayed action preparation Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 23
- 241001465754 Metazoa Species 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000000147 hypnotic effect Effects 0.000 abstract description 8
- 230000004622 sleep time Effects 0.000 abstract description 8
- 230000004620 sleep latency Effects 0.000 abstract description 7
- 230000003860 sleep quality Effects 0.000 abstract 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 229960001412 pentobarbital Drugs 0.000 description 9
- 229960002275 pentobarbital sodium Drugs 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 239000003708 ampul Substances 0.000 description 7
- 239000011521 glass Substances 0.000 description 6
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 5
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 5
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 5
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 5
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 230000028527 righting reflex Effects 0.000 description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 5
- 235000015500 sitosterol Nutrition 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 210000003321 cartilage cell Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000002220 ursolic acid group Chemical group 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical group O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 108010053098 biotin receptor Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of biological medicines, and discloses an β sitosterol derivative, a preparation method and application thereof. β sitosterol derivative can be assembled into nanoparticles with avidin. β sitosterol derivative and its nano-drug are proved by animal experiments to be capable of obviously reducing the sleep latency time of mice, obviously improving the sleep time and subliminal hypnosis and falling-asleep rate of the mice, effectively improving the sleep quality of the mice, and being used for further preparing a drug or a health care product for improving the sleep quality.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to an β sitosterol derivative as well as a preparation method and application thereof.
Background
Due to the influence of factors such as working pressure, social competition, aging of population and the like, 45.4 percent of people in China have the problem of sleep disorder and are in direct proportion to anxiety mental disorder. Sleep disorders have been experienced in about 35% of the population in the united states, with insomnia being considered to severely affect their lives in 17% of the patients and ineffective treatment in 85% of the patients. The sleep disorder seriously affects the life quality and the work efficiency of people, and researches show that the sleep disorder can cause the hypoevolutism of the body and intelligence, the memory attenuation, the reduction of the immunity of the organism and the like. Persistent sleep disorders are risk factors for depressed patients and are one of the early clinical symptoms of schizophrenia and other psychiatric disorders. At present, the sleep improvement medicines mostly focus on melatonin, paroxetine, sertraline, mirtazapine, trovadone, amitriptyline and the like, and although the substances have good sleep improvement effects, adverse reactions such as dizziness, drowsiness, hypodynamia and the like can be caused during the hypnotic dose, and drug resistance and physiological and psychological dependence are generated after long-term use. Therefore, the research and development of the hypnotic medicine with high efficiency, low dependence and no drug resistance has great social and economic significance.
β -sitosterol (β -sitosterol, BS) is one of the phytosterol components, which is widely present in various plant seeds such as vegetable oils, nuts, etc. in nature, and also present in some plant drugs, its structure is very similar to cholesterol, and has estrogenic activity, it can inhibit proliferation of human leukemia cells (G2/M block), intranuclear replication, and α -polymerization of tubulin and microtubules. β -sitosterol is widely used in the pharmaceutical industry with its characteristic biological and physicochemical properties. β -sitosterol is a white scale-like, needle-like crystal or crystalline powder, odorless, tasteless, very soluble in chloroform and carbon disulfide, soluble in ethanol or acetone, insoluble in water. β -sitosterol has cholesterol-lowering, antitussive, expectorant, and tumor-suppressing and tissue-repairing effects.
Biotin (Biotin, B) is widely applied to targeted delivery and transportation of various anti-cancer drugs and the like as a targeted ligand due to simple structure, low molecular weight, high tumor specificity and wide high expression of a Biotin receptor on the surface of a tumor tissue membrane, the Biotin is also called vitamin H and coenzyme R, is a water-soluble beneficial vitamin, also belongs to a vitamin B group, has the molecular weight of 244.31 and has a basic structure of a bicyclic structure, wherein the ring I is an imidazolone ring which is a part combined with avidin, the ring II is a thiophene ring which contains a valeric acid side chain, and the terminal carboxyl group of the thiophene ring can be connected with a biological macromolecule to form a Biotin-labeled antigen, antibody, enzyme and the like, and the chemical structure of the Biotin has an imidazolone ring which can be specifically combined with Avidin (AV) and streptavidin (streptavidin, SA), and the combination of the Biotin and the avidin has high affinity (the binding constant of about 1 × 10)-15mol/L, and can be regarded as irreversible binding), strong specificity, each can be combined with various types of large and small molecules, one molecular chain Mycosavin can be combined with four molecular biotin, twoThe streptavidin-biotin binding reaction has the advantages of multi-stage amplification effect and the like, and related technologies of the streptavidin-biotin binding reaction are widely applied to the fields of various labeling immunoassay technologies and tumor targeted therapy medicines, and a good molecular foundation is laid for building various health products based on B.
Most importantly, the improvement of solubility of β sitosterol through biotin modification and the report of sleep improvement effect of the sitosterol are not seen so far, and the specific combination of a β sitosterol derivative modified by biotin and avidin to construct nanoparticles and biomedical application are not seen.
Disclosure of Invention
To overcome the disadvantages and shortcomings of the prior art, the present invention is primarily directed to an β sitosterol derivative.
Still another object of the present invention is to provide a method for preparing the β sitosterol derivative.
Still another object of the present invention is to provide the use of the β sitosterol derivative.
Still another object of the present invention is to provide nanoparticles assembled by the β sitosterol derivatives and avidin.
It is a further object of the present invention to provide the use of the above nanoparticles.
The purpose of the invention is realized by the following technical scheme:
an β sitosterol derivative having the structure shown in formula (I):
the preparation method of the β sitosterol derivative comprises the following operation steps:
β sitosterol is dissolved in a solvent, the mixture is stirred and reacted for 1-6 h at 0 ℃ under the action of a dehydrating agent N, N' -dicyclohexylcarbodiimide or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and a catalyst on dimethylaminopyridine, then biotin is added according to the molar ratio of β sitosterol being 1:1-3 times of the mixture, the temperature is raised to room temperature from an ice bath, the mixture is stirred overnight in a dark place, filtrate is concentrated, and the mixture is recrystallized by glacial ethyl ether or isopropanol, is chromatographed or is prepared into a liquid phase for purification, and is freeze-dried to obtain the β sitosterol derivative with the structure shown in the formula (I).
The solvent is CH2Cl2DMSO or DMF; the stirring reaction time is 5 h; the room temperature was 25 ℃.
The mole ratio of the β sitosterol to the dehydrating agent to the catalyst is 1:1: 1-1: 25: 25.
The β sitosterol derivative and the application of the pharmaceutically acceptable salt thereof in preparing the sleep improving medicine or the health care product are tablets, capsules, powder, granules, oral liquid, pills, powder, sustained release preparations, solutions, suspensions, injections, microneedles, ointments, creams or suppositories.
A nanoparticle is composed of β sitosterol derivative and avidin.
The application of the nano-particles in preparing the sleep-improving medicine or health-care product. The medicine is tablet, capsule, powder, granule, oral liquid, pill, powder, sustained release preparation, solution, suspension, injection, microneedle, ointment, cream or suppository.
A schematic synthesis of β sitosterol derivatives having the structure shown in formula (I) is shown in FIG. 1.
As used herein, "pharmaceutically acceptable salts" refers to salts that retain the biological potency of the free acid and free base of the specified compound, and that are biologically or otherwise not adversely affected. Salts in this application refer to acid salts formed with organic/inorganic acids, as well as basic salts formed with organic/inorganic bases.
The principle of the invention is as follows:
the invention is based on the principle of biotin and nano-drug assembly of biotin and avidin and disease cell enrichment mediated, the solubility problem of the finished drug is solved by modifying β sitosterol with biotin, and the biotin has the advantages of good water solubility, biocompatibility, no immunogenicity and the like, can improve the drug effect, increase the selectivity, reduce the toxic and side effects, and is more suitable for clinical use.
The inventor finds that β sitosterol compound chemically modified by biotin obviously improves the solubility, and particularly can completely meet the clinical administration requirement after being assembled with avidin nanometer in the design and experimental invention.
A2% rabbit erythrocyte hemolysis test shows that the biotin-modified β sitosterol derivative or the nano preparation thereof of the invention has no erythrocyte hemolysis aggregation within 4h, and the equivalent β sitosterol dosage is more than 60 mg.
Solubility experiments show that compared with a prototype (β sitosterol is insoluble in water), the β sitosterol derivative modified by biotin has obviously improved water solubility (about 5mg/ml), and particularly has good water solubility (greater than 20mg/ml) after being assembled into a nano preparation with avidin, so that the preparation of a medicament form, vascular administration and the like are more convenient.
Compared with the prior art, the invention has the following advantages and beneficial effects:
the β sitosterol derivative modified by biotin and the β sitosterol derivative modified by biotin are specifically combined with avidin to construct a nano-drug system, so that the technical problems of poor solubility, poor curative effect, poor targeting property and the like of β sitosterol are greatly solved, and the invention has good clinical application prospect.
Drawings
FIG. 1 is a schematic diagram of B-BS synthesis.
FIG. 2 is a schematic diagram of the assembly of B-BS series and avidin into nano-drugs.
FIG. 3 is a schematic diagram of β assembly of sitosterol derivatives and avidin into nanoparticles.
Detailed description of the invention
The present invention will be described in further detail with reference to examples, but the embodiments of the present invention are not limited thereto.
EXAMPLE 1 preparation of β sitosterol derivative (B-BS) according to the invention
β sitosterol (0.15mmol) was dissolved in 60ml DMSO in dehydrating agent DCC (3.0mmol) and catalysisStirring at 0 deg.C for 6 hr under the action of DMAP (3.0mmol), adding biotin (B) at a molar ratio of β sitosterol of 1: 3, heating to room temperature 25 deg.C in ice bath, stirring overnight in dark place, concentrating filtrate, recrystallizing with glacial ethyl ether or isopropanol, purifying by chromatography or preparative liquid phase, and lyophilizing to obtain β sitosterol derivative B-BS (yield about 48%), identifying ion peak by mass spectrum [ M + H ])]+Comprises the following steps: 642.1.
1HNMR (400MHz, DMSO): characteristic peaks of biotin: 10.76-10.82(NH, 2H, broad peak), 4.47-4.65(2C-H,2H), 2.80-3.10 (CH)2,2H),3.24(CH,1H),2.32(CH2,2H),1.23-1.68(3CH26H), β characteristic peak of sitosterol 0.85-0.88(4 CH)3,12H),0.99-1.03(CH3,3H),1.08-1.38(7CH2,8CH,22H),2.09-2.31(2CH2,4H)。
IR: the infrared spectrum is obviously increased by 1725cm-1The ester carbonyl peak of (a), indicating that β sitosterol and biotin are attached via an ester linkage.
The mass spectrometry data above demonstrate that the β sitosterol derivative obtained in this example has the structure shown below:
example 2 β preparation of sitosterol derivative avidin nanoparticles
The β sitosterol derivative (B-BS) which is equal to β sitosterol 5g and prepared in example 1 is taken, firstly dissolved in a small amount of DMSO or ethanol, then diluted by water for injection, added with sodium chloride 1.0g, added with equimolar avidin (the B-BS and avidin can be assembled according to various molar ratios of 1-4: 1 as shown in figure 2), and stirred uniformly at room temperature to obtain composite β sitosterol derivative avidin nanoparticles, and the nanoparticles are characterized by a transmission electron microscope, and have the nanometer size of about 25nm (as shown in figure 3).
Example 3 β preparation of sitosterol derivative injection
β sitosterol derivative (B-BS) which is equal to β sitosterol and is prepared in example 1 is dissolved in water for injection, 5.0g of sodium chloride is added and stirred uniformly, the pH value is adjusted to 5.0 by dilute hydrochloric acid, then 0.5% of activated carbon for injection is added, the temperature is kept constant at 60 ℃ for 30min, after the carbon is removed, water for injection is added into the filtrate to 1000ml, a sterile filter membrane with the diameter of 0.22 mu m is used for filtration, 2 ml/branch is packaged in a glass curved neck ampoule, the glass curved neck ampoule is sealed in a melting mode, steam is circulated at 100 ℃ for wet heat sterilization for 40min, and then the glass curved neck ampoule is labeled for storage.
EXAMPLE 4 β preparation of sitosterol derivative avidin Nano injection
Equal to β g of sitosterol 30g of the β sitosterol derivative (B-BS) prepared in example 1 is dissolved in water for injection, 5.0g of sodium chloride and 300.0g of avidin are added and stirred uniformly, the pH value is adjusted to 5.0 by dilute hydrochloric acid, then 0.5% of activated carbon for injection is added, the temperature is kept constant at 60 ℃ for 30min, after the carbon is removed, water for injection is added into the filtrate to 1000ml, sterile filter membrane filtration with the diameter of 0.22 mu m is carried out, 2 ml/branch is packed in a glass curved neck ampoule, and the ampoule is sealed by melting and then is labeled for storage.
EXAMPLE 5 β preparation of sitosterol derivative avidin Nano injection
Equal to β g of sitosterol 30g of the β sitosterol derivative (B-BS) prepared in example 1 is dissolved in water for injection, 5.0g of sodium chloride and 150.0g of avidin are added and stirred uniformly, the pH value is adjusted to 5.0 by dilute hydrochloric acid, then 0.5% of activated carbon for injection is added, the temperature is kept constant at 60 ℃ for 30min, after the carbon is removed, water for injection is added into the filtrate to 1000ml, sterile filter membrane filtration with the diameter of 0.22 mu m is carried out, 2 ml/branch is packed in a glass curved neck ampoule, and the ampoule is sealed by melting and then is labeled for storage.
Example 6 β preparation of Freeze-dried powder of sitosterol derivatives
β sitosterol derivative (B-BS) powder prepared in example 1, which is equal to β sitosterol 20g, is added with glucose powder for injection 25g and stirred uniformly, and the mixture is aseptically subpackaged in glass curved-neck ampoules according to 40 mg/bottle, freeze-dried, sterilized by cobalt 60 radiation, sealed and then labeled for storage.
Example 7 β vascular irritation test of sitosterol derivative nanoparticles
β sitosterol derivative avidin nano injection prepared in example 4 and dissolved by trace DMSO, 40mg of water for injection, 6 experimental rabbits, 3 random groups (β sitosterol derivative avidin nano injection drug group, β sitosterol group and normal saline group), wherein normal saline is used as a control, biotin- β sitosterol injection is instilled into the left ear edge vein of the rabbits, normal saline with the same volume is instilled into the right ear edge vein, instillation is completed within 3h, blood vessels, heart, liver, spleen, lung, pancreas, kidney and brain tissues at the position of 1cm below the injection point are taken after instillation is completed, formalin solution is fixed, paraffin is embedded into slices, HE staining is performed, and digital pathology analysis and evaluation are performed.
After the administration, the rabbit is observed that the rabbit is normal in diet, hair, anus, respiration, central nervous system, four limbs activity state every day, and has no toxic manifestation, when the rabbit is about 48 hours, the killed animal is observed that the rectal mucosa is smooth and flat, and has no abnormal appearance, the rest rabbits are kept to monitor day by day, and no abnormal appearance appears, when the animal is killed in the seventh day, the animal is observed for weight and the vascular stimulation is graded according to new drug research guidelines, the pathological histological examination result of the rabbit vascular irritation test is that auricle and epidermis have no abnormality, dermal vascular endothelial cells have no swelling, capillary walls have no bleeding, necrosis or inflammatory cell infiltration, cartilage layers and cartilage cells have no hyperplasia or necrosis, cartilage cells are arranged orderly, liver, myocardial tissue, brain tissue, lung, kidney and pancreas tissue have no abnormality, physiological saline has no abnormality compared with auricle epidermis, dermal vascular endothelial cells have no swelling, vascular capillary walls have no bleeding, necrosis or inflammatory cell infiltration, the cartilage cells are arranged orderly, the cartilage layers and cartilage cells have no hyperplasia or necrosis, β, and the physiological saline solution injection shows obvious difference with β nano saline solution.
Example 8 experimental study in mice of β sitosterol derivatives prepared in example 1 to improve sleep
Experimental animals: 180 healthy male Kunming mice are purchased by SPF experimental animal center, the weight of the mice is 18-22 g, and the mice and feed are purchased in SPF experimental animal center, 4-5 weeks; placing the mixture in a feeding room with the temperature of 22-25 ℃ and the relative humidity of 50-70 percent.
The test method comprises the following steps:
1) grouping and administration, wherein animals are randomly divided into 3 experimental groups after being pre-fed for 1 week, the first group is subjected to a direct sleep experiment and an experiment for prolonging the sleep time of the pentobarbital sodium, the second group is subjected to a subliminal dose hypnosis experiment of the pentobarbital sodium, and the third group is subjected to a sleep latency experiment of the pentobarbital sodium, 50 mice are randomly divided into 5 groups according to the body weight in each experimental group, 10 animals in each group are set as a control group, β low, medium and high dose groups of sitosterol derivatives (dose groups are set according to body weights of 50, 100 and 200 mg/kg), β sitosterol (200mg/kg body weight dose group), ursolic acid group (50mg/kg body weight dose group), and the animals are subjected to gastric lavage administration, and the control group is subjected to the same solvent drenching for 1 time/d for 30.
2) Direct sleep experiments: after the stomach is not irrigated again, whether the sleep phenomenon appears is observed, and the sleep takes the disappearance of the righting reflex as an index. When the mouse is placed in the back lying position, the mouse can turn over to the right position immediately, if the mouse cannot turn over for more than 60 seconds, the turning-over reflection is considered to disappear, and the mouse enters sleep. The recovery of the righting reflex is the awakening of the animal, the period from disappearance of the righting reflex to recovery is the sleeping time of the animal, and the number of sleeping animals and the sleeping time of the control group and each dosage group are recorded.
3) Experiment for prolonging the sleep time of the sodium pentobarbital comprises the steps of injecting 50mg/kg of sodium pentobarbital into the abdominal cavity of each group of animals 15 minutes after last intragastric administration, wherein the injection amount is 0.2m L/20 g of the animals, and observing whether the test sample prolongs the sleep time of the sodium pentobarbital by taking disappearance of positive turning reflex as a sleep-entering judgment standard.
4) Pentobarbital sodium subthreshold dose hypnosis experiment includes injecting pentobarbital sodium of 25mg/kg body weight into abdominal cavity of animals of each group 15 minutes after last gastric lavage, wherein the injection amount is 0.2m L/20 g body weight, and the number of the animals falling asleep within 30 minutes is recorded by taking the disappearance of righting reflex for more than 1 minute as a sleep judgment standard.
5) Pentobarbital sodium sleep latency period experiment, after 15 minutes of last gastric lavage, 280mg/kg of pentobarbital sodium is injected into the abdominal cavity of each group of animals, the injection amount is 0.2m L/20 g of body weight, the disappearance of righting reflex is taken as an index, and the influence of the tested sample on the sleep latency period of the pentobarbital sodium is observed.
The experimental results are as follows:
1) the influence on the development and growth weight of mice is shown in the following table 1, compared with a control group, β sitosterol has almost no effect, the ursolic acid group and the β sitosterol derivative in and at high dose have obvious growth promotion effect, the β sitosterol derivative high dose group has the best effect, the weight of the mice is increased by more than 25%, and the difference is very obvious and statistically different.
Table 1: effect on mouse body weight
Remarking: statistical differences were significant compared to control group (p < 0.05); statistical differences were very significant (p < 0.01); AV + -SD is the mean + -error value.
2) The observation of the direct sleep effect of the mice shows that in the direct sleep test, the number of sleeping animals and the sleep time of each dose group of β sitosterol group, ursolic acid group and β sitosterol derivative group are 0, which indicates that the two substances have no direct hypnotic effect on the mice and can be used for detecting the following three indexes.
Table 2: observation of the Effect of direct sleep in mice
3) As shown in Table 3, in the experiment for prolonging the sleep time of sodium pentobarbital, β sitosterol derivatives in each dose group and ursolic acid group can prolong the sleep time of sodium pentobarbital compared with the control group, so that β sitosterol derivatives in middle and high dose groups have the best effect and have statistically significant difference.
Table 3: effect on prolonging sleep time of pentobarbital sodium in mice
Remarking: statistical differences were significant compared to control group (p < 0.05); statistical differences were very significant (p < 0.01);
4) the influence on the subliminal dose hypnosis effect of the sodium pentobarbital in the mice is shown in the table 4, β sitosterol derivatives and ursolic acid can obviously improve the sleep rate of the mice, compared with a control group, the sleep rate of the mice is respectively improved by 20 percent, 50 percent, 60 percent and 20 percent, and the effect is best in a high-dose group.
Table 4: effect on subliminal dose hypnosis of sodium pentobarbital in mice
Remarking: statistical differences were significant compared to control group (p < 0.05); statistical differences were very significant (p < 0.01);
5) the influence on the sleep latency of mice induced by sodium pentobarbital in the mice is shown in Table 5, the sleep latency of the mice in a control group is 26.99min, β sitosterol derivatives in each dose group and ursolic acid in the mice are shortened, wherein the latency of the high dose group is shortest and has a statistical difference with the control group.
Table 5: influence on sleep latency of mice induced by sodium pentobarbital
Remarking: statistical differences were significant compared to control group (p < 0.05); statistical differences were very significant (p < 0.01);
combining the results, β sitosterol derivative has obvious efficacy of improving the sleep of mice, and has better effect in dose dependence.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (9)
2. the process for the preparation of β sitosterol derivatives according to claim 1, characterized by comprising the following operating steps:
β sitosterol is dissolved in a solvent, the mixture is stirred and reacted for 1-6 h at 0 ℃ under the action of a dehydrating agent N, N' -dicyclohexylcarbodiimide or 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride and a catalyst on dimethylaminopyridine, then biotin is added according to the molar ratio of β sitosterol being 1:1-3 times of the mixture, the temperature is raised to room temperature from an ice bath, the mixture is stirred overnight in a dark place, filtrate is concentrated, and the mixture is recrystallized by glacial ethyl ether or isopropanol, is chromatographed or is prepared into a liquid phase for purification, and is freeze-dried to obtain the β sitosterol derivative with the structure shown in the formula (I).
3. The method of claim 2, wherein: the solvent is CH2Cl2DMSO or DMF; the stirring reaction time is 5 h; the room temperature was 25 ℃.
4. The method according to claim 2, wherein the molar ratio of the β sitosterol to the dehydrating agent to the catalyst is 1:1:1 to 1:25: 25.
5. The use of β sitosterol derivatives and their pharmaceutically acceptable salts according to claim 1 for the preparation of a medicament or health product for improving sleep.
6. Use according to claim 5, characterized in that: the medicine is tablet, capsule, powder, granule, oral liquid, pill, powder, sustained release preparation, solution, suspension, injection, microneedle, ointment, cream or suppository.
7. A nanoparticle assembled from the β sitosterol derivative of claim 1 and avidin.
8. Use of the nanoparticle according to claim 7 for the preparation of a medicament or health product for improving sleep.
9. Use according to claim 8, characterized in that: the medicine is tablet, capsule, powder, granule, oral liquid, pill, powder, sustained release preparation, solution, suspension, injection, microneedle, ointment, cream or suppository.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010136016.0A CN111423484B (en) | 2020-03-02 | 2020-03-02 | Beta sitosterol derivative and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010136016.0A CN111423484B (en) | 2020-03-02 | 2020-03-02 | Beta sitosterol derivative and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111423484A true CN111423484A (en) | 2020-07-17 |
CN111423484B CN111423484B (en) | 2021-08-31 |
Family
ID=71548017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010136016.0A Active CN111423484B (en) | 2020-03-02 | 2020-03-02 | Beta sitosterol derivative and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111423484B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114041600A (en) * | 2021-12-15 | 2022-02-15 | 哈尔滨工业大学重庆研究院 | Preparation method of anthocyanin-loaded phytosterol delivery system |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0296581A (en) * | 1988-09-29 | 1990-04-09 | Shiseido Co Ltd | Biotin ester and skin ointment and hair tonic using the ester |
CN104098594A (en) * | 2014-07-16 | 2014-10-15 | 中国科学院昆明植物研究所 | Biotin-podophyllotoxin esterified derivative and pharmaceutical composition thereof, as well as preparation methods and applications of derivative and pharmaceutical composition |
-
2020
- 2020-03-02 CN CN202010136016.0A patent/CN111423484B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0296581A (en) * | 1988-09-29 | 1990-04-09 | Shiseido Co Ltd | Biotin ester and skin ointment and hair tonic using the ester |
CN104098594A (en) * | 2014-07-16 | 2014-10-15 | 中国科学院昆明植物研究所 | Biotin-podophyllotoxin esterified derivative and pharmaceutical composition thereof, as well as preparation methods and applications of derivative and pharmaceutical composition |
Non-Patent Citations (2)
Title |
---|
谢普: "《中草药鉴别与应用》", 31 July 2017 * |
陈经佳等: "DCC法合成胆甾醇酯", 《浙江化工》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114041600A (en) * | 2021-12-15 | 2022-02-15 | 哈尔滨工业大学重庆研究院 | Preparation method of anthocyanin-loaded phytosterol delivery system |
CN114041600B (en) * | 2021-12-15 | 2023-05-16 | 哈尔滨工业大学重庆研究院 | Preparation method of anthocyanin-loaded phytosterol delivery system |
Also Published As
Publication number | Publication date |
---|---|
CN111423484B (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5294509B2 (en) | Cycloastragenol monoglucoside, process for its production and use as a pharmaceutical composition | |
WO2017162108A1 (en) | Pillararene complex, preparation method, pharmaceutical composition and use thereof | |
WO2002036592A1 (en) | Remedies for arachidonic acid-induced skin diseases | |
CN111333692B (en) | Betulinic acid derivative and preparation method and application thereof | |
CA2781436A1 (en) | Arachidonic acid analogs and methods for analgesic treatment using same | |
EA029649B1 (en) | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof | |
CN111423484B (en) | Beta sitosterol derivative and preparation method and application thereof | |
WO2017092230A1 (en) | Biflavone compound and uses thereof for treating cancers and preparing drugs | |
CN104557909B (en) | 3- acyloxy replaces dextrorotation deoxidation tylophorinine derivative, its preparation method and pharmaceutical composition and purposes | |
CN113546089B (en) | Application of 1-ethyl-3, 7-dimethyl xanthine in preparation of medicine for treating pneumonia | |
CN101961318A (en) | Lappaconitine sustained release microspheres for injection and preparation method thereof | |
CN116251080A (en) | Application of solanesol in preparing medicine for preventing, treating or relieving chronic pain | |
JPS6043351B2 (en) | Manufacturing method for geriatric drugs | |
KR20200112012A (en) | Compositions for skin wound healing and regeneration comprising (R)-Ginsenoside Rg3 | |
CN102219740A (en) | 1,2,3,4,5,6,7,8-octahydro-9-phenylacetamide acridine as well as preparation method and medicinal application thereof | |
JP5698741B2 (en) | 13a- (S) Deacidified Tyrophorinine Salt, Pharmaceutical Composition and Use | |
CN111253462A (en) | Betulin derivative and preparation method and application thereof | |
CN101070338A (en) | Tanshinone IIA potassium sulfonate for preparing medicine for preventing and treating myocardial ischemia and cerebral ischemia and anoxia | |
CN102512435A (en) | Application of 5,6,4'-trihydroxyl flavone-7-O-beta-D-glucuronide methyl ester and medicinal composition as well as preparation thereof | |
WO2019201268A1 (en) | Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof | |
TW201113525A (en) | Methods for diagnosing diabetes and determining effectiveness of treatments | |
CN108721257B (en) | Application of patchouli alcohol in preparation of endothelium-independent vasodilator | |
CN101327215B (en) | Medicament composition containing protoberberine type alkaloids | |
CN116172994B (en) | Application of anthraquinone derivative in preparation of anti-pancreatitis medicine | |
CN110384710B (en) | Medicine and combination product for preventing and/or treating pain and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |